Mind the gap: Potential for rebounds during antiangiogenic treatment breaks

John M.L. Ebos, Roberto Pili

Research output: Contribution to journalArticle

11 Scopus citations


VEGF pathway inhibitors have shown benefits in many cancers, yet many (often controversial) questions remain about whether vascular and tumor regrowth can occur when therapy is stopped. Marked increases in endothelial cell proliferation could play a role in putative rebounds, potentially influencing overall efficacy, dosing schedules, and presurgical intervention strategies.

Original languageEnglish (US)
Pages (from-to)3719-3721
Number of pages3
JournalClinical Cancer Research
Issue number14
StatePublished - Jul 15 2012


ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this